September 2008 Oncology News International

Publication
Article

Cover Story

The surgeon who challenged the breast ca paradigm

Payer's budget to get right targeted drug to right patient

New paradigm in pancreatic cancer promotes coordinated patient care

DEPARTMENTS

Focus on Breast Cancer

In elderly with early breast ca, stick with standard chemo

Herceptin erases survival difference between HER2- patients

Focus on Colon Cancer

Adding oxaliplatin to FULV trends toward better survival in stage II/III colon cancer

News & Analysis

Reimbursement for new RT lags behind implementation

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
A study aimed to determine the variables that correlated with extravasation rates in patients receiving radiation injection therapy.
Related Content
84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer

84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer

David J. Portman;Timothy Pluard;Jane L. Meisel, MD;Kelly Shanahan;Sarah Sammons, MD;Elizabeth Attias
April 26th 2025
Article
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study

86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study

Hope S. Rugo, MD;Sara M. Tolaney, MD, MPH;Nancy Chan;Erika P. Hamilton, MD;Marina Sharifi;Kristine Rinn;Wassim McHayleh;Rinat Yerushalmi;Neelima Vidula, MD;Joyce O’Shaughnessy, MD;Guiseppe Curigliano;Javier Cortés, MD;Paula Muñoz Romero;Bartomeu Piza Vallespir;Kathy Puyana Theall;Alessandro Paoli;Monica Binaschi;Tomer Wasserman;Virginia Kaklamani, MD, DSc
April 25th 2025
Article
Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Final analysis data from the phase 3 ALCYONE trial support using frontline daratumumab-containing regimens for those with transplant-ineligible NDMM.

Daratumumab Combo Yields Sustained Benefits in Transplant-Ineligible NDMM

Russ Conroy
April 25th 2025
Article

Final analysis data from the phase 3 ALCYONE trial support using frontline daratumumab-containing regimens for those with transplant-ineligible NDMM.

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.